Loading company…
Masswill develops clinical mass spectrometry products and in vitro diagnostic systems.
Masswill develops products in clinical mass spectrometry, including the Wuxin Spectrum marker combination for cardiovascular disease management and the Maijike automated sample processing system. The company is based in Shanghai, China, and was founded in 2022. In June 2024, it raised CNY 20 million in pre-Series A funding. The funds are intended to support product commercialization, clinical translation, registration, and distribution.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in